PT - JOURNAL ARTICLE AU - Shoukry, Rachel F Smallwood AU - Clark, Michael G AU - Floeter, Mary Kay TI - Resting State Functional Connectivity is Decreased Globally Across the <em>C9orf72</em> Mutation Spectrum AID - 10.1101/2020.08.10.20171991 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.10.20171991 4099 - http://medrxiv.org/content/early/2020/08/11/2020.08.10.20171991.short 4100 - http://medrxiv.org/content/early/2020/08/11/2020.08.10.20171991.full AB - A repeat expansion mutation in the C9orf72 gene causes amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or symptoms of both, and has been associated with gray and white matter changes in brain MRI scans. We used graph theory to examine the network properties of brain function at rest in a population of mixed-phenotype C9orf72 mutation carriers (C9+). Twenty-five C9+ subjects (presymptomatic, or diagnosed with ALS, behavioral variant FTD (bvFTD), or both ALS and FTD) and twenty-six healthy controls underwent resting state fMRI. When comparing all C9+ subjects with healthy controls, both global and connection-specific decreases in resting state connectivity were observed, with no substantial reorganization of network hubs. However, when analyzing subgroups of the symptomatic C9+ patients, those with bvFTD (with and without comorbid ALS) show remarkable reorganization of hubs compared to patients with ALS alone (without bvFTD), indicating that subcortical regions become more connected in the network relative to other regions. Additionally, network connectivity measures of the right hippocampus and bilateral thalami increased with increasing scores on the Frontal Behavioral Inventory, indicative of worsening behavioral impairment. These results indicate that while C9orf72 mutation carriers across the ALS-FTD spectrum have global decreased resting state brain connectivity, phenotype-specific effects can also be observed at more local network levels.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01925196Funding StatementThe study was supported by the intramural program of the National Institutes of Health, National Institute of Neurological Disorders and Stroke. Z01 NS003146.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All subjects gave written informed consent in accordance with protocols approved by the NIH IRB, FWA #: 00005897.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe corresponding author will make de-identified data available upon reasonable request.